368 related articles for article (PubMed ID: 26956047)
1. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.
Francis L; Guo ZS; Liu Z; Ravindranathan R; Urban JA; Sathaiah M; Magge D; Kalinski P; Bartlett DL
Oncotarget; 2016 Apr; 7(16):22174-85. PubMed ID: 26956047
[TBL] [Abstract][Full Text] [Related]
2. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.
Liu Z; Ravindranathan R; Li J; Kalinski P; Guo ZS; Bartlett DL
Oncoimmunology; 2016 Mar; 5(3):e1091554. PubMed ID: 27141352
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
4. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
5. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
6. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
8. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
9. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
11. An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer.
Ding L; Gao Q; Xu Z; Cai L; Chen S; Zhang X; Cao P; Chen G
Adv Sci (Weinh); 2022 Jan; 9(2):e2103470. PubMed ID: 34747156
[TBL] [Abstract][Full Text] [Related]
12. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice.
Komorowski M; Tisonczyk J; Kolakowska A; Drozdz R; Kozbor D
Viruses; 2018 Aug; 10(9):. PubMed ID: 30149659
[TBL] [Abstract][Full Text] [Related]
14. Cancer-cell-secreted CXCL11 promoted CD8
Gao Q; Wang S; Chen X; Cheng S; Zhang Z; Li F; Huang L; Yang Y; Zhou B; Yue D; Wang D; Cao L; Maimela NR; Zhang B; Yu J; Wang L; Zhang Y
J Immunother Cancer; 2019 Feb; 7(1):42. PubMed ID: 30744691
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Virotherapy and the Tumor Microenvironment.
Berkey SE; Thorne SH; Bartlett DL
Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
[TBL] [Abstract][Full Text] [Related]
16. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.
Guo ZS; Parimi V; O'Malley ME; Thirunavukarasu P; Sathaiah M; Austin F; Bartlett DL
Gene Ther; 2010 Dec; 17(12):1465-75. PubMed ID: 20703311
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
18. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
[TBL] [Abstract][Full Text] [Related]
19. Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity.
Chang CY; Tai JA; Li S; Nishikawa T; Kaneda Y
Oncotarget; 2016 Jul; 7(27):42195-42207. PubMed ID: 27259252
[TBL] [Abstract][Full Text] [Related]
20. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]